Market Cap
$44.3B
IQV
IQVIA HOLDINGS INC.
$257.29 ▼ -1.32%
Prev close $260.72Market cap$44.3B
ConsensusStrong Buy
12-mo target$288.74 (+12.1%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (5 insiders)High Impact Filing (7/10)30 New Institutional Positions20 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on IQV right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Strong Buy (82%)
Inst. Holders
50 funds
Inst. Value
$22.9B
Inst. Activity
30 buys / 20 sells
Insider Activity
$0.00 buy / $29.9M sell
Insider Net $
-$29.9M
SEC Reports
9
Congressional
2 trades
Price chart 30d -2.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 28, 2026 clinical_trial_readout
T-90d Trial Readout: Oregovomab (Phase 3)
Trial: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Fol
Sep 2, 2026 Insider
Berkshire James G. sold 2,668 shares
See Remarks @ $261.33 ($697.2K)
Sep 2, 2026 Insider
Berkshire James G. disposed of 2,713 shares
See Remarks @ $261.54 ($709.6K)
Sep 2, 2026 Insider
Aug 4, 2026 SEC Berkshire James G. acquired via exercise 5,381 shares
See Remarks @ $131.82 ($709.3K)
Four IQVIA insiders sold a total of ~$14.8M in shares over a 7-day window ending 7/31/2026, including a large multi-leg
CLUSTER — Impact 4/10
CEO Ari Bousbib and CFO Eric Sherbet sold a combined $2.35M in open-market transactions on July 29, 2026, following IQVI
CLUSTER — Impact 2/10
IQVIA reported Q2 2026 results that beat consensus on both revenue and adjusted EPS, with revenue of $4,368M (+8.7% YoY)
8-K — Impact 7/10
Jun 30, 2026 Inst.
NORGES BANK — NEW
2,264,944 shares ($437.6M)
Analyst ratings buy % -1.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
82% rate it Buy or better · 28 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 29, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Sep 28, 2026 | Truist Securities | REITERATE | Buy | 55% |
| Sep 17, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | 55% |
| Jul 29, 2026 | JP Morgan | MAINTAIN | Overweight | 55% |
| Jul 29, 2026 | Stifel | MAINTAIN | Buy | 54% |
| Jul 29, 2026 | TD Cowen | MAINTAIN | Buy | 56% |
| Jul 29, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jul 29, 2026 | BMO Capital | MAINTAIN | Outperform | 53% |
| Jul 29, 2026 | Baird | MAINTAIN | Outperform | 54% |
| Jul 13, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 9 | 14 | 5 | 0 | 0 | 82% | |
| Aug 1, 2026 | 8 | 14 | 6 | 0 | 0 | 79% | |
| Jul 1, 2026 | 8 | 14 | 7 | 0 | 0 | 76% | |
| Jun 1, 2026 | 9 | 15 | 6 | 0 | 0 | 80% | |
| May 1, 2026 | 10 | 17 | 4 | 0 | 0 | 87% | |
| Apr 1, 2026 | 10 | 17 | 4 | 0 | 0 | 87% | |
| Mar 1, 2026 | 10 | 14 | 6 | 0 | 0 | 80% | |
| Feb 1, 2026 | 10 | 14 | 6 | 0 | 0 | 80% |
Price targets
Where 19 covering analysts think IQV trades over the next 12 months.
$288.74 +12.1% upside Buy
Current$257.65 Low$250.00 Median$280.00 High$345.00 19 analysts
$250.00$345.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
9 SEC filing reports analyzed · 2 bullish, 0 bearish, 0 mixed, 7 neutral · avg impact 3.6/10.
NEUTRALCLUSTER4/10
Four IQVIA insiders sold a total of ~$14.8M in shares over a 7-day window ending 7/31/2026, includin
Aug 4, 2026
NEUTRALCLUSTER2/10
CEO Ari Bousbib and CFO Eric Sherbet sold a combined $2.35M in open-market transactions on July 29,
Aug 1, 2026
BULLISH8-K7/10
IQVIA reported Q2 2026 results that beat consensus on both revenue and adjusted EPS, with revenue of
Jul 28, 2026
NEUTRALCOURT-RULING1/10
A federal district court granted summary judgment against IQVIA on a single-plaintiff TCPA claim ove
Jul 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
Clinical Trial
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Sep 28, 2026
clinical_trial_readout
T-90d Trial Readout: Oregovomab (Phase 3)
Trial: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Sponsor: CanariaB
Sep 27, 2026
clinical_trial_readout
T-90d Trial Readout: Oregovomab (Phase 3)
Trial: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Sponsor: CanariaB
Sep 16, 2026
short_volume
Short Volume: IQV — 57.4% short (0.4M / 0.7M)
Short: 399,165 | Exempt: 1,863 | TRF Vol: 695,232 | Short Ratio: 57.4% | Off-exchange volume (dark pool + OTC)
Sep 10, 2026
short_volume
Short Volume: IQV — 65.0% short (0.4M / 0.6M)
Short: 408,473 | Exempt: 143 | TRF Vol: 628,117 | Short Ratio: 65.0% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $3.27 | $3.22–$3.54 | 9.1% | -0.0% | 10↑ 4↓ | $4.4B | 17 |
| Next Q | $3.65 | $3.58–$3.81 | 6.8% | +0.1% | 6↑ 8↓ | $4.5B | 17 |
| Current FY | $12.97 | $12.87–$13.38 | 8.8% | +0.0% | 21↑ 0↓ | $17.4B | 22 |
| Next FY | $14.47 | $13.90–$15.48 | 11.6% | +0.1% | 18↑ 2↓ | $18.5B | 22 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $3.272 | — |
| 7d ago | $3.273 | -0.001 |
| 30d ago | $3.273 | -0.001 |
| 60d ago | $3.273 | -0.001 |
| 90d ago | $3.251 | +0.021 |
Institutional ownership
Which big funds own IQV (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $22.9B total value (118,849,342 shares) as of 2026-Q2. Top holders: BlackRock,, HARRIS, VANGUARD. Net buying activity: 30 institutions added/increased vs 20 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 14,549,693 | $2.8B | 12.3% | — |
| HARRIS ASSOCIATES L P | 12,183,830 | $2.4B | 10.3% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 10,905,053 | $2.1B | 9.2% | — |
| STATE STREET CORP | 7,508,244 | $1.5B | 6.3% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 7,501,993 | $1.4B | 6.3% | — |
| JPMORGAN CHASE & CO | 6,139,775 | $1.2B | 5.2% | — |
| Artisan Partners Limited Partnership | 4,743,434 | $916.5M | 4.0% | — |
| Boston Partners | 4,466,016 | $865.5M | 3.8% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 4,454,134 | $857.2M | 3.7% | — |
| Invesco Ltd. | 3,275,141 | $632.8M | 2.8% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 2,264,944 | — | $437.6M |
| GOLDMAN SACHS GROUP INC | ADD | 1,177,280 | 1,949,797 | +65.6% | $376.7M |
| ALLIANCEBERNSTEIN L.P. | TRIM | 2,878,897 | 1,643,102 | -42.9% | $280.2M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | 992,190 | 1,250,053 | +26.0% | $241.5M |
| CANADA PENSION PLAN INVESTMENT BOARD | TRIM | 1,999,089 | 1,246,820 | -37.6% | $240.9M |
| FMR LLC | TRIM | 1,850,127 | 1,212,670 | -34.5% | $234.3M |
| Orbis Allan Gray Ltd | DOUBLED | 218,248 | 1,101,165 | +404.5% | $212.8M |
| LAZARD ASSET MANAGEMENT LLC | TRIM | 1,858,834 | 975,420 | -47.5% | $188.5M |
| Sumitomo Mitsui Trust Group, Inc. | TRIM | 1,225,851 | 831,826 | -32.1% | $160.7M |
| ROYAL BANK OF CANADA | ADD | 401,428 | 797,956 | +98.8% | $154.2M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
17 insiders, 50 transactions. Net -$29.9M — $0.00 bought, $29.9M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Berkshire James G. | See Remarks | SELL | 2,668 | $261.33 | $697.2K |
| Sep 2, 2026 | Berkshire James G. | See Remarks | D | 2,713 | $261.54 | $709.6K |
| Sep 2, 2026 | Berkshire James G. | See Remarks | EXERCISE | 5,381 | $131.82 | $709.3K |
| Aug 3, 2026 | STAUB W RICHARD | See Remarks | SELL | 5,500 | $232.68 | $1.3M |
| Jul 31, 2026 | Patel Bhavik | See Remarks | SELL | 1,855 | $235.27 | $436.4K |
| Jul 29, 2026 | BOUSBIB ARI | See Remarks | SELL | 4,465 | $247.10 | $1.1M |
| Jul 29, 2026 | BOUSBIB ARI | See Remarks | SELL | 4,584 | $246.85 | $1.1M |
| Jul 29, 2026 | Sherbet Eric | See Remarks | SELL | 5,000 | $249.16 | $1.2M |
| Jul 29, 2026 | BOUSBIB ARI | See Remarks | EXERCISE | 156,206 | $78.21 | $12.2M |
| Jul 29, 2026 | BOUSBIB ARI | See Remarks | SELL | 53,191 | $244.78 | $13.0M |
Congressional trades
IQV trades disclosed by members of Congress, with disclosure delay.
2 members · 1 buys / 1 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | Kevin Hern | R | HOUSE | SELL | $50,001 - $100,000 | Iqvia Holdings Inc | Apr 6, 2026(22d) |
| Dec 29, 2025 | Markwayne Mullin | R | SENATE | BUY | $15,001 - $50,000 | Iqvia Holdings Inc | Jan 16, 2026(19d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for IQV.
Shares short
4,116,522
Settlement Sep 15, 2026
Change vs prior
+9.0%
Semi-monthly cycle
Days to cover
3.0
At avg daily volume
Of shares outstanding
≈2.5%
Estimate — not % of float
All IQV filing & press-release reports (9)
- CLUSTER reportAug 4, 2026
- CLUSTER reportAug 1, 2026
- 8-K reportJul 28, 2026
- COURT-RULING reportJul 3, 2026
- COURT-RULING reportJul 2, 2026
- 8-K reportJun 11, 2026
- 8-K reportJun 5, 2026
- 8-K reportJun 3, 2026
- DEFA14A reportFeb 27, 2026